Navigation Links
Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
Date:1/7/2008

administered daily. Patients in the first cohort will receive a dose of XL184 that is below the maximum tolerated dose (MTD) identified in the ongoing phase 1 trial of XL184, in combination with erlotinib. Subsequent cohorts will receive erlotinib in combination with escalating doses of XL184 until the MTD is reached. In the phase 2 portion of the study, patients will be randomized to receive XL184 at the MTD alone or in combination with erlotinib. Additionally, correlative studies will evaluate MET amplification and EGFR mutational status. MET and EGFR signaling activity will be assessed in tumor and surrogate tissue.

Data from an ongoing phase 1 trial of XL184 in patients with advanced malignancies were presented in October 2007 at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Abstract #A152). Investigators reported that anti-tumor activity had been observed in a variety of cancers at doses that are not associated with significant toxicity. There were 33 patients available for safety, pharmacokinetic and tumor response analyses as of the June 22, 2007 cutoff; further data were also provided for six additional patients after the cutoff. Of seven patients with medullary thyroid cancer (MTC), three had partial responses (two confirmed and one unconfirmed) as of the date of the AACR-NCI- EORTC Conference. In addition, as of such date, six of the seven patients had tumor shrinkage and one had non-measurable disease. All seven assessable patients with MTC experienced a rapid decrease in plasma levels of calcitonin, a marker frequently elevated in MTC, and six of the seven patients had a decrease in the tumor marker carcinoembryonic antigen. All seven MTC patients remain on study. In addition, one patient with a neuroendocrine tumor has an unconfirmed partial response. In total, 15 patients with various malignancies have had stable disease lasting from 3 - 20 months, including nine patients with stable disease for m
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
2. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
3. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
4. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
5. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
6. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
7. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
8. GlaxoSmithKline Accelerates Review of Exelixis XL880
9. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
10. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
11. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014  Decision Resources Group finds ... eligible for biologic therapy, only a proportion ... gastroenterologists cite patients, discomfort with biological therapy ... rates, followed by cost-related issues and payer ... biologics, Janssen Biotech,s Remicade and AbbVie,s Humira ...
(Date:9/17/2014)... -- Bronstein, Gewirtz & Grossman, LLC is investigating potential ... PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") (NasdaqGS: ... to contact Peretz Bronstein or his investor ... or 212-697-6484. The investigation focuses on ... federal securities laws. On September 16, 2014, ...
(Date:9/17/2014)... PRAIRIE, Minn. , Sept. 17, 2014 ... and global market leader of advanced imaging modalities for ... Ultrasound System in two live cases at the Transcatheter ... The cases were presented from Medstar Washington Hospital ... York-Presbyterian Hospital/Columbia University Medical Center ( New York, ...
Breaking Medicine Technology:The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2ACIST Launches HDi High-Definition IVUS 2ACIST Launches HDi High-Definition IVUS 3
... , JERUSALEM , Jan. ... company, announced today that it has granted Novartis an option to ... Permeability Enhancer (TPE) technology for use with certain related small molecule ... a separate but related agreement, the MPM Bio IV NVS Strategic ...
... , FRANKLIN LAKES, N.J. , Jan. 19 ... scheduled to present at the following investor conferences: , Brian Griffin ... Global Healthcare Services Conference on Monday, January 25, 2010 at ... New York ; , David B. Snow Jr. , Medco chairman ...
Cached Medicine Technology:Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products 2Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products 3Medco to Present at Upcoming Investor Conferences 2
(Date:9/17/2014)... 17, 2014 As kinship care continues ... who cannot live with their parents, emphasis on kinship ... to enhance services and supports for kinship caregivers and ... National Kinship Care Conference is being held this week ... best practice, policy, program and service development for kinship ...
(Date:9/17/2014)... Final Cut Pro X plugin developers have ... Pixel Film Studios. , “ProBlue 5k is a compilation of ... to epic,” said Christina Austin, CEO of Pixel Film Studios. ... a definite game changer.” , ProBlue 5k is the ultimate ... filmmaker ! This footage compilation of over 100 anamorphic flares ...
(Date:9/17/2014)... first-of-its-kind research study was announced today that will ... impact long-term wellness and contribute to healthy aging. ... Center and funded through a $10 million unrestricted ... Fund, WELL aims to identify lifestyle and environmental ... and wellness as they age. WELL will be ...
(Date:9/17/2014)... September 17, 2014 In its latest blog ... and believes that having family close by during a stay ... not the process is successful, is highlighting a member of ... in the lives of addicts across the country and around ... therapy can reduce the blood pressure, heart rate, and stress ...
(Date:9/17/2014)... these sound like the ideas of a ... components of an exciting new approach to imaging ... of metastatic prostate cancer, scientists at Virginia Commonwealth ... Medicine and Johns Hopkins Medical Institutions have provided ... could revolutionize doctors, ability to see tumors that ...
Breaking Medicine News(10 mins):Health News:Arizona’s Children Association Kinship Service Providers Invited to Present at the CWLA National Conference 2Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3
... of Economy, Vet Difficulties Demonstrate Urgency; Advances in ... Mental Health America, the country,s oldest and ... mentally healthier lives, today called for action on ... for Mental Health."To view the Multimedia News Release, ...
... Customers; Reaches 400,000 Live User Milestone; Named #1 SSO ... identity and access management (IAM) solutions are the most ... the best performance in the Company,s history. In ... new user licenses. In addition, the Company reached ...
... at the University of Texas Medical Branch at Galveston ... fever virus uses to disarm the defenses of infected ... in humans, inflicting liver damage, blindness and even death ... Rift Valley fever also afflicts cattle, goats and sheep, ...
... N.M., Feb. 17 Exagen Diagnostics, Inc., which ... for research and analytic specific reagents to clinical ... Alsobrook, Ph.D., has been named vice president and ... oversees Exagen,s day-to-day operations, company alliances and genomic ...
... Effect on Executive Function and Functional Capacity are ... According to a New Report from Decision ResourcesWALTHAM, ... the world,s leading research and advisory firms for ... drug were to receive formal regulatory approval for ...
... procedure rooms offer faster and more accurate diagnosis and ... Medical Center today announces the completion of its state-of-the-art ... Now located on the second level of the ... with three fully functional state-of-the-art catheterization labs (cath labs) ...
Cached Medicine News:Health News:Video: On 100th Anniversary, Mental Health America Declares 'It's Time for Mental Health' 2Health News:Video: On 100th Anniversary, Mental Health America Declares 'It's Time for Mental Health' 3Health News:Video: On 100th Anniversary, Mental Health America Declares 'It's Time for Mental Health' 4Health News:Sentillion Announces 2008 as the Best Year in the Company's History 2Health News:Sentillion Announces 2008 as the Best Year in the Company's History 3Health News:Scientists uncover secrets of potential bioterror virus 2Health News:Exagen Diagnostics Names John Alsobrook, Ph.D., Vice President and Chief Operating Officer 2Health News:A Drug That Receives Regulatory Approval for Cognitive Impairment Associated With Schizophrenia Would Earn a Higher Patient Share in the United States Than in Europe 2Health News:A Drug That Receives Regulatory Approval for Cognitive Impairment Associated With Schizophrenia Would Earn a Higher Patient Share in the United States Than in Europe 3Health News:St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine 2Health News:St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine 3Health News:St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine 4Health News:St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine 5
... key clinical and economic issues of cerclage ... designed to maximize tension control while minimizing ... combines efficient instrumentation with a simple technique. ... is indicated for general orthopaedic trauma surgery ...
OmniAccess&trade Hip Retractor System sets a new standard in hip exposure. It provides constant, absolute exposure of the acetabulum during total hip arthroplasty and revision procedures....
... Many of DePuy's aggressive innovations have become ... to be equalled. The AML Total ... to efficiently address and effectively meet the ... arthroplasty. With greater than 15 years ...
The Endotrac™ System includes an Obturator, Slotted Cannula, Synovial Elevator, Ligament Probe, Ligament Rasp, Blade Handle, two Retractors and sterilizable tray. The Endotrac&trade....
Medicine Products: